Tanox is a pharmaceutical company that specializes in the development of biologic drugs for the treatment of serious diseases. Their products aim to address unmet medical needs and improve patients' quality of life.
Incorporated in 1986 as a biopharmaceutical company focused on antibody-based therapeutics.
Initially, Tanox focused on research and development collaborations with other pharmaceutical companies.
In 1998, they entered into a partnership with Genentech to develop Xolair, a breakthrough treatment for severe allergic asthma.
In 2006, Tanox was acquired by Genentech and became a subsidiary of the company.
Under Genentech, Tanox continued its research and development efforts in the field of biologic drugs.
Regeneron Pharmaceuticals is a biotechnology company that develops and commercializes pharmaceutical products for the treatment of serious medical conditions.
Amgen is a multinational biopharmaceutical company that specializes in the development of innovative therapies for various diseases, including cancer, cardiovascular disease, and inflammatory disorders.
Biogen is a biotechnology company that focuses on the development and commercialization of therapies for neurological and neurodegenerative diseases, autoimmune disorders, and rare genetic diseases.
Xolair is a biologic drug used for the treatment of severe allergic asthma and chronic idiopathic urticaria.
Tanox develops various other biologic drugs targeting different medical conditions, including immunological disorders and cancer.
The main product of Tanox is Xolair, a biologic drug used for the treatment of severe allergic asthma and chronic idiopathic urticaria.
Tanox was founded in 1986.
Tanox was acquired by Genentech in 2006.
Some of the competitors of Tanox include Regeneron Pharmaceuticals, Amgen, and Biogen.
Tanox's biologic drugs target a range of medical conditions, including severe allergic asthma, chronic idiopathic urticaria, immunological disorders, and cancer.
